A major global brewer has raised concerns that the rising use of weight-loss drugs like Wegovy could dampen demand for alcohol, potentially impacting sales in pubs and bars. The company, the world’s second-largest brewer, suggests that medications such as GLP-1 treatments may reduce alcohol cravings, leading to lower consumption. In a recent presentation to hospitality businesses, it warned of possible effects like increased fullness and fewer drinks per customer. The warning highlights a growing trend that could reshape drinking habits and industry revenue.
World’s second largest brewer says use of drugs such as Wegovy can reduce desire to drink alcohol• Business live – latest updatesHeineken has warned British bars and pubs that the boom in popularity of weight-loss drugs could lead to a fall in sales of beer and cider.The world’s second-largest brewer sent a presentation to British hospitality customers earlier this month that said the use of GLP-1 medication – such as Ozempic and Wegovy – could reduce the desire to drink alcohol. This in turn could result in “fullness and fewer serves” of pints in pubs and bars, it added. Continue reading...
